trial · primary record
povorcitinib
Hidradenitis Suppurativa (HS)
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 600 |
| Primary completion | 2028-02-28 |
| Primary endpoint | Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) |
| Registry ID | NCT06855498 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:03.581Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06855498
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.